<DOC>
	<DOCNO>NCT02055118</DOCNO>
	<brief_summary>Study HGT-HIT-094 multicenter study design determine effect clinical parameter neurodevelopmental status monthly IT administration idursulfase-IT 10 mg 12 month pediatric patient Hunter syndrome cognitive impairment previously receive tolerated minimum 4 month therapy Elaprase .</brief_summary>
	<brief_title>Study Intrathecal Idursulfase-IT Administered Conjunction With Elaprase® Pediatric Patients With Hunter Syndrome Early Cognitive Impairment</brief_title>
	<detailed_description>Elaprase , large molecular protein , expect cross blood brain barrier administer intravenously . A revised formulation idursulfase , idursulfase-IT , differs intravenous ( IV ) formulation , Elaprase , develop suitable delivery cerebrospinal fluid ( CSF ) via intrathecal administration . Mucopolysaccharidosis II ( MPS II ) rare , X-linked , inherited disease affect males nearly exclusively . The disease cause absence , deficiency , activity lysosomal enzyme , iduronate-2-sulfatase ( I2S ) act cleave O-linked sulfate moiety glycosaminoglycan ( GAG ) molecules dermatan sulfate heparan sulfate . Study HGT-HIT-094 control , randomize , two-arm , open-label , assessor-blinded , multicenter study determine effect clinical parameter neurodevelopmental status monthly IT administration idursulfase-IT 10 mg 12 month pediatric patient Hunter syndrome cognitive impairment previously receive tolerated minimum 4 month therapy Elaprase . Pediatric patient 3 year age enrol separate substudy evaluate safety efficacy idursulfase-IT . The separate substudy open label single arm . Patients enrol substudy receive idursulfase-IT treatment follow schedule study visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Inclusion Criteria Inclusion Criteria Pivotal Study Patients must meet follow criterion consider eligible randomization pivotal study : 1 . The patient male ≥3 &lt; 18 year age time informed consent . ( Patients young 3 year age may enrol separate substudy provide meet inclusion criterion , provide . ) 2 . The patient must document diagnosis MPS II . 3 . The patient evidence Screening Hunter syndromerelated cognitive impairment define follow : A patient ≥3 &lt; 13 year age must one follow criterion ( 3a OR 3b ) : 1 . A GCA score ≥55 ≤85 OR 2 . If patient GCA score Screening &gt; 85 , must evidence decrease GCA score ≥10 point 12 month previously document test result observational study HGTHIT090 . A patient ≥13 &lt; 18 year age must follow criterion ( 3c AND 3d ) : 3 . A GCA score ≥55 ≤85 . AND 4 . There must evidence decrease GCA score ≥10 point 12 month previously document 4 . The patient receive tolerated minimum 4 month therapy Elaprase period immediately prior Screening . 5 . The patient must sufficient auditory capacity , hear aid ( ) , need , Investigator 's judgment complete require protocol test must compliant wear hear aid ( ) , need , schedule testing day . 6 . The patient 's parent ( ) legally authorize guardian ( ) must voluntarily sign Institutional Review Board/Independent Ethics Committee approve informed consent form relevant aspect study explain discuss . Consent patient 's parent ( ) legally authorize guardian ( ) patient 's assent , applicable , must obtain prior start study procedure . Inclusion Criteria Substudy Patients must meet follow criterion consider eligible enrollment separate substudy : 1 . The patient male &lt; 3 year age time informed consent . 2 . The patient must document diagnosis MPS II . 3 . The patient evidence Screening Hunter syndromerelated cognitive impairment 4 . The patient receive tolerated minimum 4 month therapy Elaprase period immediately prior Screening . 5 . The patient must sufficient auditory capacity , hear aid ( ) , need , Investigator 's judgment complete require protocol test must compliant wear hear aid ( ) , need , schedule testing day . 6 . The patient 's parent ( ) legally authorize guardian ( ) must voluntarily sign Institutional Review Board/Independent Ethics Committee approve informed consent form relevant aspect study explain discuss . Consent patient 's parent ( ) legally authorize guardian ( ) must obtain prior start study procedure . Exclusion Criteria Patients meet follow criterion eligible randomize pivotal study enrol separate substudy : 1 . The patient clinically significant nonHunter syndromerelated CNS involvement ( FragileX syndrome ) judge Investigator likely interfere accurate administration interpretation protocol assessment . 2 . The patient large chromosomal deletion complex rearrangement include deletion FMR1 and/or FMR2 gene . 3 . The patient significant medical psychiatric comorbidity ( y ) might affect study data confound integrity study result . 4 . The patient contraindication performance lumbar puncture musculoskeletal/spinal abnormality risk abnormal bleeding . 5 . The patient history complication previous lumbar puncture technical challenge conduct lumbar puncture potential risk would exceed possible benefit patient . 6 . The patient open CSF pressure upon lumbar puncture exceed 30.0 cm H2O . 7 . The patient experience infusionrelated anaphylactoid event ( ) evidence consistent severe adverse event related treatment Elaprase , Investigator 's opinion , may pose unnecessary risk patient . 8 . The patient receive cord blood bone marrow transplant time receive blood product transfusion within 90 day prior Screening . 9 . The patient history poorly control seizure disorder . 10 . The patient unable comply protocol ( eg , significant hearing vision impairment , clinically relevant medical condition make implementation protocol difficult , unstable social situation , know clinically significant psychiatric/behavioral instability , unable return safety evaluation , otherwise unlikely complete study ) , determine Investigator . 11 . The patient enrol another clinical study involve clinical investigation use investigational product ( drug [ intrathecal/spinal ] device ) within 30 day prior study enrollment time study . 12 . The patient know suspected hypersensitivity anesthesia think unacceptably high risk anesthesia due compromise airways condition . 13 . The patient condition contraindicate described SOPHAPORT Mini S IDDD Instructions Use ( IFU ) , include limited presence CSF shunt device patient .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hunter disease</keyword>
	<keyword>MPS II</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>hunter syndrome</keyword>
	<keyword>ert treatment</keyword>
	<keyword>hunter 's disease</keyword>
	<keyword>iduronate sulfatase</keyword>
	<keyword>MPS society</keyword>
	<keyword>mp 2</keyword>
	<keyword>enlarged adenoid</keyword>
	<keyword>hunter 's syndrome</keyword>
	<keyword>iduronate 2 sulfatase</keyword>
	<keyword>chronic ear infection</keyword>
	<keyword>mucopolysaccharide</keyword>
	<keyword>hunter syndrome therapy</keyword>
	<keyword>hunter 's syndrome treatment</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>hunter syndrome treatment</keyword>
	<keyword>elaprase</keyword>
	<keyword>MPSII</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>mp diagnosis</keyword>
	<keyword>mp symptom</keyword>
	<keyword>idursulfase</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter 's disease treatment</keyword>
	<keyword>MPS2</keyword>
</DOC>